These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29800105)

  • 21. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
    Asselah T; Reesink H; Gerstoft J; de Ledinghen V; Pockros PJ; Robertson M; Hwang P; Asante-Appiah E; Wahl J; Nguyen BY; Barr E; Talwani R; Serfaty L
    Liver Int; 2018 Sep; 38(9):1583-1591. PubMed ID: 29461687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects.
    Hsieh YC; Lin CL; Hung CH; Chen CH; Tung SY; Lin CY; Hu TH; Lu SN; Chien RN; Sheen IS
    J Viral Hepat; 2020 May; 27(5):505-513. PubMed ID: 32039536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Preclinical and clinical properties of elbasvir (ERELSA
    Kinoshita K; Iwasa T; Asante-Appiah E; Nakamura K
    Nihon Yakurigaku Zasshi; 2017; 150(1):41-53. PubMed ID: 28690275
    [No Abstract]   [Full Text] [Related]  

  • 24. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
    Stein K; Stoehr A; Klinker H; Teuber G; Naumann U; John C; Heyne R; Serfert Y; Niederau C; Zeuzem S; Berg T; Wiegand J;
    Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):76-83. PubMed ID: 32956186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of a sensitive and robust strategy for micellar electrokinetic chromatographic analysis of sofosbuvir in combination with its co-formulated hepatitis C antiviral drugs.
    Rageh AH; Abdel-Aal FAM; Pyell U
    J Chromatogr A; 2020 Apr; 1616():460795. PubMed ID: 31918849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
    Rockstroh JK; Nelson M; Katlama C; Lalezari J; Mallolas J; Bloch M; Matthews GV; Saag MS; Zamor PJ; Orkin C; Gress J; Klopfer S; Shaughnessy M; Wahl J; Nguyen BY; Barr E; Platt HL; Robertson MN; Sulkowski M
    Lancet HIV; 2015 Aug; 2(8):e319-27. PubMed ID: 26423374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of anti-Hepatitis C virus, sofosbuvir and daclatasvir, in pure form, human plasma and human urine using micellar monolithic HPLC-UV method and application to pharmacokinetic study.
    Zidan DW; Hassan WS; Elmasry MS; Shalaby AA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jun; 1086():73-81. PubMed ID: 29660665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
    Feng HP; Guo Z; Ross LL; Fraser I; Panebianco D; Jumes P; Fandozzi C; Caro L; Talaty J; Ma J; Mangin E; Huang X; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
    J Antimicrob Chemother; 2019 Mar; 74(3):710-717. PubMed ID: 30541077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Column reversed-phase high-performance liquid chromatographic method for simultaneous determination of rabeprazole sodium and domperidone in combined tablet dosage form.
    Sabnis SS; Dnvandev DN; Jadhav VY; Gandhi SV
    J AOAC Int; 2008; 91(2):344-8. PubMed ID: 18476346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole.
    Feng HP; Vaddady P; Guo Z; Liu F; Panebianco D; Levine V; Caro L; Butterton JR; Iwamoto M; Yeh WW
    Clin Transl Sci; 2017 Sep; 10(5):360-365. PubMed ID: 28625018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of chronic hepatitis C infection with crushed elbasvir/grazoprevir administered via a percutaneous endoscopic gastrostomy tube.
    Yap JE; Jaiswal P; Ton L; Szynkarek R; Attar BM; Gandhi S
    J Clin Pharm Ther; 2018 Oct; 43(5):730-732. PubMed ID: 29906312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants.
    Cheung TT; Yan Chiu JW; Yuen MF; Ling Lam KS; Yung Cheung BM; Feng HP; Yeh WW; Wang J; Li W; Zhao XM; Wang Z; Mu S
    Clin Ther; 2018 May; 40(5):719-732.e1. PubMed ID: 29724498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
    Braun DL; Hampel B; Kouyos R; Nguyen H; Shah C; Flepp M; Stöckle M; Conen A; Béguelin C; Künzler-Heule P; Nicca D; Schmid P; Delaloye J; Rougemont M; Bernasconi E; Rauch A; Günthard HF; Böni J; Fehr JS;
    Clin Infect Dis; 2019 Feb; 68(4):569-576. PubMed ID: 30107485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
    Ankrom W; Sanchez RI; Yee KL; Fan L; Mitra P; Wolford D; Triantafyllou I; Sterling LM; Stoch SA; Iwamoto M; Khalilieh S
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Grazoprevir/elbasvir fixed-dose combination for hepatitis C.
    Gamal N; Andreone P
    Drugs Today (Barc); 2016 Jul; 52(7):377-85. PubMed ID: 27540596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis.
    Yao Y; Yue M; Wang J; Chen H; Liu M; Zang F; Li J; Zhang Y; Huang P; Yu R
    Can J Gastroenterol Hepatol; 2017; 2017():8186275. PubMed ID: 28164081
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C.
    Sulejmani N; Jafri SM; Gordon SC
    Expert Opin Drug Metab Toxicol; 2016; 12(3):353-61. PubMed ID: 26849059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
    Feng HP; Caro L; Fandozzi C; Chu X; Guo Z; Talaty J; Panebianco D; Dunnington K; Du L; Hanley WD; Fraser IP; Mitselos A; Denef JF; De Lepeleire I; de Hoon JN; Vandermeulen C; Marshall WL; Jumes P; Huang X; Martinho M; Valesky R; Butterton JR; Iwamoto M; Yeh WW
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial: real-life data confirm efficacy of elbasvir/grazoprevir in HCV patients with severe kidney disease.
    Rumi MG; Occhipinti V
    Aliment Pharmacol Ther; 2018 Jul; 48(2):226-227. PubMed ID: 29939410
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis.
    Asselah T; Zeuzem S; Reau N; Hwang P; Long J; Talwani R; Robertson MN; Haber BA
    Curr Med Res Opin; 2020 Aug; 36(8):1325-1332. PubMed ID: 32459122
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.